Endovastec™ Minos® Stent Graft Enters 2019 Shanghai Municipal Recommendation Directory for Innovative Products

Shanghai, China – Shanghai Municipal Commission of Economy and Informatization published the 2019 Shanghai Municipal Recommendation Directory for Innovative Products recently. The Minos® Abdominal Aortic Stent-Graft and Delivery System (“Minos® Stent Graft”), which is self-developed by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”), was successfully granted entry into the directory.

 

The application and review proceedings of Shanghai Municipal Recommendation Directory for Innovative Products are organized by Shanghai Municipal Commission of Economy and Informatization. The work aims to implement Shanghai’s strategies of expediting the building of an internationally influential center for scientific and technological innovations in the city as well as “Driven by innovation and develop with transformations”. The work is expected to promote the marketing and commercialization of innovative products to propel the transformations and upgrades of industries as well as the innovation and development of companies in Shanghai. The work will result in the development of new economy and formation of new momentum.

 

As a new generation abdominal aortic aneurysm (AAA) stent graft system self-developed by Endovastec™, Minos® Stent Graft System is designed to treat AAA with proximal neck lengths of no less than 15mm. It is the only device that decreases delivery sheath’s outside diameter to 14F (<5mm) among the similar Chinese-made devices with self-owned intellectual property. It imposes significantly less requirements for vascular access in AAA Endovascular Aneurysm Repair procedure. Minos® Stent Graft provides a better solution for the patients diagnosed with the AAA with complex anatomies and especially benefit those with access artery stenosis and tortuosity.

 

After being granted entry into the Special Review and Approval Process for Innovative Medical Devices with the National Medical Products of China (NMPA) in 2017, Minos® Stent Graft received the NMPA approval in March 2019 and the CE Mark in September 2019. In addition, a post-marketing clinical study of Minos® Stent Graft has been designated as Project in the Field of Cooperation between Companies, Universities, Institutes and Hospitals under the 2019 Shanghai Municipal Action Plan for Scientific and Technological Innovation. The entry of Minos® Stent Graft into the 2019 Shanghai Municipal Recommendation Directory for Innovative Products symbolizes the long-standing focuses of Endovastec™ on the development and innovation of products as well as the promotion of the commercialization and mass manufacturing for scientific and technological research results. In the future, Endovastec™ will adhere to a development strategy on the basis of innovation to create more highly innovative and high added-value products and integrated therapeutic solutions. Endovastec™ will make bigger contributions to Shanghai’s building of a center for scientific and technological centers.